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A B S T R A C T
Purpose
Colon cancers exhibiting DNA mismatch repair (MMR) defects demonstrate distinct clinical and
pathologic features, including better prognosis and reduced response to fluorouracil (FU) –based
chemotherapy. This prospective study investigated adjuvant chemotherapy containing FU and
irinotecan in patients with MMR deficient (MMR-D) colon cancers.
Patients and Methods
Cancer and Leukemia Group B 89803 randomly assigned 1,264 patients with stage III colon cancer
to postoperative weekly bolus FU/leucovorin (LV) or weekly bolus irinotecan, FU, and LV (IFL). The
primary end point was overall survival; disease-free survival (DFS) was a secondary end point.
Tumor expression of the MMR proteins, MLH1 and MSH2, was determined by immunohisto-
chemistry (IHC). DNA microsatellite instability was also assessed using a panel of mono- and
dinucleotide markers. Tumors with MMR defects were those demonstrating loss of MMR protein
expression (MMR-D) and/or microsatellite instability high (MSI-H) genotype.
Results
Of 723 tumor cases examined by genotyping and IHC, 96 (13.3%) were MMR-D/MSI-H.
Genotyping results were consistent with IHC in 702 cases (97.1%). IFL-treated patients with
MMR-D/MSI-H tumors showed improved 5-year DFS as compared with those with mismatch
repair intact tumors (0.76; 95% CI, 0.64 to 0.88 v 0.59; 95% CI, 0.53 to 0.64; P  .03). This
relationship was not observed among patients treated with FU/LV. A trend toward longer DFS was
observed in IFL-treated patients with MMR-D/MSI-H tumors as compared with those receiving
FU/LV (0.57; 95% CI, 0.42 to 0.71 v 0.76; 95% CI, 0.64 to 0.88; P  .07; hazard ratio interaction
between tumor status and treatment, 0.51; likelihood ratio P  .117).
Conclusion
Loss of tumor MMR function may predict improved outcome in patients treated with the IFL
regimen as compared with those receiving FU/LV.
J Clin Oncol 27:1814-1821. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Colorectal cancer (CRC) develops through accu-
mulated genetic changes that produce loss of
tumor suppressor genes and activation of onco-
genes. In sporadic CRC, these changes occur
through at least two distinct mechanisms. The
first, termed chromosomal instability (CIN), is
associated with loss of heterozygosity at multi-
ple tumor suppressor loci, particularly 5q, 17p,
and 18q.1 This type of genomic instability oc-
curs in approximately 80% to 85% of sporadic
CRC. A second subset demonstrates DNA mis-
match repair (MMR) deficiency, characterized by
an inability to repair single nucleotide DNA mis-
matches. This defect alters the size of di-, tri- and
tetra-dinucleotide repeat sequences known as
microsatellites, and this genomic instability is
also termed microsatellite instability (MSI).2,3
Approximately 15% to 20% of sporadic CRCs
demonstrate high levels of MSI (termed MSI-H).
These CRCs may develop because MSI fosters
inactivating mutations in tumor suppressors
containing microsatellites, such as transform-
ing growth factor  RII4 and BAX.5 In most
sporadic cases, MSI occurs when the promoter
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 27  NUMBER 11  APRIL 10 2009
1814 © 2009 by American Society of Clinical Oncology
region of the mismatch repair gene, MLH1, is silenced by CpG
island hypermethylation.6,7
Identification of MSI requires DNA extraction from tumor and
normal tissue, which can be technically challenging and time-
consuming. Immunohistochemistry (IHC) can also detect loss of
MMR protein expression, and IHC identification of MLH1 and
MSH2, two MMR proteins most commonly lost in sporadic CRC, is a
widely available clinical test to distinguish MMR deficient (MMR-D)
from mismatch repair intact (MMR-I) tumors.8
Retrospective studies show that the clinical behavior of MMR-D/
MSI-H CRCs is different than those without this characteristic. MMR-
D/MSI-H tumors are more commonly located in the right colon and
are more frequently poorly differentiated and mucin-containing.9-12
Despite these adverse histopathologic features, MMR-D/MSI-H tu-
mors may have better treatment outcome than tumors with CIN.
Studies comparing patients with MMR-D/MSI-H CRC with stage-
matched controls show that patients with MMR-D/MSI-H tumors
experience longer survival than those whose tumors lack this charac-
teristic.13,14 A meta-analysis of 32 CRC studies estimated a combined
hazard ratio (HR) for overall survival (OS) associated with MSI-H of
0.65 (95% CI, 0.59 to 0.71).14
A limited number of retrospective studies examined adjuvant
chemotherapy for patients with stage II or III MSI-H CRC. These
studies indicate that, unlike patients whose tumors demonstrate CIN,
those with MSI-H tumors experience no benefit with regimens con-
taining fluorouracil (FU).15-17 Cancer and Leukemia Group B
(CALGB) 89803 was a phase III randomized trial comparing FU/
leucovorin (LV) with irinotecan, FU, and LV (IFL) for postoperative
adjuvant treatment of stage III or high-risk stage II colon cancer. This
study prospectively determined whether patients with MMR-D/
MSI-H tumors were more likely to achieve better outcome overall or
were more likely to respond to IFL.
PATIENTS AND METHODS
Characteristics of Study Population
Patients with histologically confirmed stage III colon cancer were en-
rolled onto CALGB protocol 89803 (Table 1). All patients underwent com-
plete surgical resection and started chemotherapy between postoperative days
21 to 56. The primary end point was OS; DFS was a secondary end point.
Additional secondary aims addressed the relationship between tumor-
associated risk factors and treatment outcome and required submission of
paraffin blocks containing tumor and normal tissue to the CALGB Pathology
Coordinating Office at Ohio State University. This protocol was reviewed by
the institutional review board of each center, and all patients gave written
informed consent before participation.
Trial Structure and Organization
This trial was conducted by CALGB with participation by the North
Central Cancer Treatment Group, National Cancer Institute of Canada Clin-
ical Trials Group, Eastern Cooperative Oncology Group, Southwest Oncology
Group, and the National Cancer Institute Cancer Trials Support Unit. The
CALGB data safety monitoring board reviewed safety data twice yearly and
efficacy data at protocol-specified intervals in accordance with CALGB poli-
cies. The CALGB Statistical Center at Duke University in Durham, NC, main-
tained the clinical and laboratory database.
Treatment
After central registration, eligible patients were assigned by computer
(randomized fixed block) to receive either IFL or FU/LV. The FU/LV group
received the Roswell Park regimen, consisting of LV 500 mg/m2 intravenously
over 2 hours, with a bolus of FU 500 mg/m2 by intravenous injection 1 hour
after initiation of LV. Treatments were to be administered weekly for 6 con-
secutive weeks followed by a 2-week rest, for a total of four cycles or 32 weeks
of therapy. The IFL group received irinotecan 125 mg/m2 over 90 minutes
followed immediately by intravenous bolus injection of LV 20 mg/m2, then FU
500 mg/m2 also by intravenous bolus injection. Treatment was to be given for
4 consecutive weeks followed by a 2-week rest for five cycles or 30 weeks.
Further details concerning the treatment portion of this trial have been pub-
lished previously.18
Detection of Tumor MSI
Formalin-fixed, paraffin-embedded primary tumor and normal colon
specimens were obtained for each case from the CALGB Pathology Coordi-
nating Office. Central pathology review confirmed the histology of each spec-
imen; blocks were sectioned at 4 m for IHC and 10 m for DNA extraction.
Laboratory analysis was performed at Brigham and Women’s Hospital in
Boston, MA, without knowledge of the patient’s clinical outcome.
IHC detected the presence of MLH1 and MSH2 proteins in primary
tumor specimens. Positive controls were provided by examining staining of
normal colonic mucosa from each case; tumors known to lack MLH1 or
MSH2 were stained concurrently and served as negative controls. All cases
were scored as positive (defined as  10% of tumor cells staining) or negative
( 10% tumor cells staining). Cases designated as MMR-D were those with a
negative IHC score for either MLH1 or MSH2, and cases designated MMR-I
retained expression of both proteins. Each case was scored by two independent
experts in gastrointestinal pathology (C.C.C., H.P.H.). In cases of disagree-
ment (four cases, 0.05%), a third reviewer (M.R.) examined the case to provide
the final score.
DNA extracted from each tumor was amplified by standard polymerase
chain reaction using microsatellite markers defined during the 1998 National
Cancer Institute Workshop on Microsatellite Instability19: BAT25, BAT26,
D17S250, D5S346, ACTC, D18S55, BAT40, D10S197, BAT34c4, and MycL. In
most cases, normal control tissue was obtained from a separate, nontumor
tissue block. When this was not possible, non-neoplastic control tissue was
obtained by microdissection. Whenever necessary, microdissection was per-
formed to enrich tumor specimens for neoplastic cells, ensuring a minimum of
60% tumor within the sample. Tumors were designated MSI-H if instability
was identified at  50% of the loci screened, MSI-low (MSI-L) if at least one
but  50% of the loci showed instability, and microsatellite stable (MSS) if all
loci were stable. For analysis, MSI-L and MSS cases were combined (MSI-L/S).
A minimum of five successfully amplified loci were required for classification.
Statistical Methods
The study goal was to determine whether tumor MMR status was asso-
ciated with outcome for patients with stage III colon cancer. The primary end
point was OS measured from entry onto the clinical trial until death from any
cause. DFS was measured from study entry until documented progression of
disease or death from any cause. A secondary goal was to determine the
relationship between MMR status assigned by genotyping with that of IHC.
Median follow-up was estimated among surviving patients. Relationships
between tumor MMR status and clinical pathologic factors were studied using
the 2 and Satterthwaite t tests. The interaction between treatment arm and
MMR status was tested using a Cox model, and the log-rank test was used for
survival comparisons among categories defined by MMR status and treatment
and within MMR and treatment subgroups. The proportional hazards model
was used to make survival comparisons controlling for treatment and other
clinicopathologic factors. Because of small sample sizes, only one additional
prognostic variable was considered in each model simultaneously with treat-
ment. The Kaplan-Meier method was used to estimate the DFS and OS curves
and the 3-year and 5-year survival probabilities. Agreement between MMR
status as determined by genotyping and IHC was estimated using the  statis-
tic. All outcome analyses were conducted on the subset of patients in which
there was agreement between methods. Data were analyzed with continued
follow-up for DFS and OS as of March 10, 2008. All statistical analyses were
performed by CALGB statisticians.
Colon Cancer Adjuvant Treatment Response and Tumor MMR Status
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RESULTS
Determination of Microsatellite Stability Status
Specimens were available for analysis from 986 (78%) of the
1,264 patients enrolled on CALGB 89803. Of these, 63 (6.4%) were
insufficient for analysis as a result of lack of adequate tumor and/or
normal tissue. IHC to detect MLH1 was successfully performed on
783 of 792 cases attempted. For MSH2, IHC was successfully per-
formed on 782 of 792 cases attempted. MSI status by IHC was inde-
terminate on 1.1% of tumors. A total of 106 (13.4%) cases were
MMR-D based on loss of MLH1 or MSH2, and 677 (85.5%) were
MMR-I (Tables 2 and 3). MLH1 expression was lost in 102 of the
tumors, and four lacked expression of MSH2. Polymerase chain reac-
tion amplification of microsatellite loci was successfully performed on
846 of 923 cases attempted. Of these, 137 (14.8%) were designated
MSI-H and 709 (76.8%) were MSI-L/S.
A total of 723 patients had tumors successfully scored by both
IHC and DNA microsatellite analysis (Table 3). The methods were in
agreement in 702 cases (97.1%), with most of the difference accounted
for by tumors that were MSI-H by DNA analysis but MMR-I by IHC.
The  measure of agreement between the methods was estimated
to be   0.88 with 95% CI (0.84 to 0.93) indicating good to
excellent agreement.20
















P †No. % No. % No. % No. %
Treatment .729
FU/LV 629 49.8 348 49.6 46 47.9 302 49.8
FU/LV  irinotecan 635 50.2 354 50.4 50 52.1 304 50.2
Age, years .116
Median 61 62 66 61
Range 21-85 24-85 24-85 24-85
Sex .039
Male 702 55.5 384 54.7 43 44.8 341 56.3
Female 562 44.5 318 45.3 53 55.2 265 43.7
Extracellular mucin  .0001
Yes 125 9.9 68 9.7 27 28.1 41 6.8
No 1076 85.1 611 87.0 67 69.8 544 89.8
Unknown 63 5.0 23 3.3 2 8.7 21 3.5
Site of tumor‡  .0001
Proximal 713 56.4 399 56.8 88 91.7 311 51.3
Distal 521 41.2 297 42.3 8 8.3 289 47.7
Unknown 30 2.4 6 0.9 0 0 6 1.0
Tumor grade  .0001
Well differentiated 70 5.5 32 4.6 2 2.1 30 5.0
Moderately differentiated 861 68.1 491 69.9 47 49.0 444 73.3
Poorly differentiated or undifferentiated 304 24.1 172 24.5 47 49.0 127 21.0
Unknown 29 2.3 5 0.7 0 0 5 0.8
Lymph node status
No. of positive nodes
Median 2 3 2 3
Range 0-29 1-29 1-23 1-29 .705
Node ratio .005
Median 0.23 0.22 0.18 0.23
Range 0-1.3 0.01-1 0.03-1 0.01-1
Mean 0.30 0.31 0.25 0.32
Standard deviation 0.25 0.25 0.22 0.25
Abbreviations: IHC, immunohistochemistry; MMR-D, mismatch repair deficient; MMR-I, mismatch repair intact; FU, fluorouracil; LV, leucovorin.
Analysis method  cases with agreement between genotyping and immunohistochemistry to detect MLH1 and MSH2.
†P value for the comparison between MMR-D/microsatellite instability high and MMR-I/microsatellite instability low and stable tumors.
‡Proximal  cecum, ascending colon, hepatic flexure, transverse colon; distal  splenic flexure, descending colon, sigmoid colon.
Table 2. Characterization of Tumor Microsatellite Status
Characteristic
Immunohistochemistry Genotyping
No. % No. %
No. of cases attempted 792 923
Result
MMR-D (MSI-H) 106 13.4 137 14.8
MMR-I (MSI-L/S) 677 85.5 709 76.8
Indeterminate 9 1.1 77 8.3
Abbreviations: MMR-D, mismatch repair deficient; MSI-H, microsatellite
instability high; MMR-I, mismatch repair intact; MSI-L/S, microsatellite insta-
bility low/stable.
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Relationships Between Tumor MMR Status and
Clinicopathologic Factors
Overall median follow-up was 6.65 years. No significant differ-
ences were found by age, sex, nodal status, site of primary, or primary
tumor differentiation between patients with and without tumor sam-
ples for MMR analysis. Patients with MMR-D/MSI-H tumors had
significantly more proximal tumors (2 P  .0001), poorly/undiffer-
entiated tumors (2 P  .0001), and tumors containing extracellular
mucin (50%; 2 P  .0001). The nodal ratio (number of positive
nodes divided by number of nodes sampled) was significantly
lower among patients with MMR-D/MSI-H tumors (Satterthwaite
t test P  .005), and women had more MMR-D/MSI-H tumors (2
P  .03). There were no significant differences between MMR-D and
MMR-I tumors by age, treatment, or number of positive lymph nodes
(Table 1).
Relationship Between Tumor MMR Status
and Prognosis
Analysis was conducted on data captured as of March 10, 2008,
representing median follow-up of greater than 6.0 years; median OS
and DFS have not yet been reached. The primary outcome was the
difference in OS between patients receiving IFL and FU/LV. For the
entire cohort, the probability of OS at 5 years was 0.70 with IFL and
0.72 with FU/LV, and the probability of DFS at 5 years was 0.59 for IFL
and 0.62 for FU/LV (Fig 1).
We determined whether survival probability depended on MMR
status, irrespective of treatment assignment (Table 4). For cases with
IHC/genotyping agreement (n  702), there was no difference in OS
or DFS between patients with MMR-D/MSI-H and MMR-I/MSI-L/S
tumors (Fig 1). The estimated HR for the OS comparison was 0.86
(95% CI, 0.57 to 1.29; log-rank P  .44). The 5-year probability of OS
was 0.73 for MMR-D/MSI-H cases (95% CI, 0.64 to .82) and 0.71 for
MMR-I/MSI-L/S cases (95% CI, 0.68 to 0.75). Similarly for DFS, the
estimated HR was 0.61 (95% CI, 0.57 to 0.64; log-rank P .15; Table
5). The estimated 5-year DFS was 0.67 for MMR-D/MSI-H cases
(95% CI, 0.57 to 0.76) and 0.60 for MMR-I/MSI-L/S cases (95% CI,
0.56 to 0.64). Similar results were obtained by analyses using solely the
IHC or the DNA genotyping results.






NOTE. A total of 723 patients had both genotyping and immunohistochem-
istry results (702 patients had agreement between methods).
Abbreviations: MMR-D, mismatch repair deficient; MMR-I, mismatch repair
intact; MSI-H, microsatellite instability high; MSI-L/S, microsatellite instability
low/stable.
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Fig 1. (A) Overall survival (OS) by
treatment for the entire 89803 cohort
(n  1,264); (B) disease-free survival
(DFS) by treatment for the entire 89803
cohort (n  1,264); (C) OS by mismatch
repair (MMR) status for all patients ana-
lyzed for MMR (n  702); (D) DFS by
MMR status for all patients analyzed for
MMR (n  702). FU, fluorouracil; LV,
leucovorin; IFL, irinotecan, fluorouracil,
and leucovorin; NA, not applicable.
Colon Cancer Adjuvant Treatment Response and Tumor MMR Status
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Predictive Value of MMR Status
Tumor MMR status did not predict OS, either for analysis com-
paring MMR-D/MSI-H to MMR-I/MSI-L/S tumors within each
treatment arm (combined prognostic and predictive analysis) or for a
predictive analysis comparing treatment with FU/LV to treatment
with IFL for each genomic category (Table 4; Fig 2). Patients treated
with IFL whose tumors were MMR-D/MSI-H had better 5-year DFS
than those whose tumors were MMR-I/MSI-L/S, with HR of 0.76
(95% CI, 0.64 to 0.88) versus 0.59 (95% CI, 0.53 to 0.64), respectively
(P  .03). This relationship was not observed for patients treated with
FU/LV (Table 5; Appendix Fig A1, online only). In a predictive anal-
ysis, DFS for patients with MMR-D/MSI-H tumors was compared
among those receiving FU/LV and IFL. This showed a trend toward
improved DFS for patients treated with IFL, with an HR of 0.76 (95%
CI, 0.64 to 0.88) for IFL and 0.57 (95% CI, 0.42 to 0.71) for FU/LV
(P  .07). Patients whose tumors were MMR-I/MSI-L/S did not show
a similar trend (Table 5; Appendix Fig A2, online only). Finally, there
was a trend toward longer DFS among patients with MMR-D tumors
treated with IFL versus no difference in DFS by MMR status among
patients treated with FU/LV (HR interaction, 0.51; likelihood ratio
P  .117). The analyses reported were conducted for cases with
genotype and IHC agreement (n  702). Each analysis was also
performed using genotype-only and IHC-only tumor characteriza-
tions. The results for both OS and DFS were essentially unchanged
(data not shown).
Among patients with MMR-D/MSI-H tumors, a multivariable
analysis was conducted to determine the relative significance of treat-
ment arm (IFL; FU/LV) with each of the following prognostic vari-
ables: sex (male/female), age at study entry, extracellular mucin
( 50%;  50%), tumor location (distal/proximal), differentiation
(moderate/well; poor/undifferentiated), and nodal ratio. Treatment
arm remained marginally associated with DFS in this subgroup in the
Table 4. Effect of Tumor MSI Status on Treatment Outcome for OS
Treatment Group 5-Year OS 95% CI No. Log-Rank P HR 95% CI
Prognostic analysis
All patients analyzed 0.72 0.68 to 0.75 702
All patients with MMR-D/MSI-H tumors 0.73 0.64 to 0.82 96 .44
All patients with MMR-I/MSI-L/S tumors 0.71 0.68 to 0.75 606 0.86 0.57 to 1.29
Predictive analysis: within treatment arm
Treated with FU/LV
Patients with MMR-D/MSI-H tumors 0.67 0.53 to 0.81 46 .88
Patients with MMR-I/MSI-L/S tumors 0.72 0.67 to 0.78 302 1.04 0.61 to 1.79
Treated with IFL
Patients with MMR-D/MSI-H tumors 0.78 0.66 to 0.89 50 .23
Patients with MMR-I/MSI-L/S tumors 0.70 0.65 to 0.76 304 0.69 0.37 to 1.28
Predictive analysis: within tumor subtype
Patients with MMR-D/MSI-H tumors
Treated with FU/LV 0.67 0.53 to 0.81 46 .27
Treated with IFL 0.78 0.65 to 0.89 50 0.65 0.30 to 1.41
Patients with MMR-I/MSI-L/S tumors
Treated with FU/LV 0.72 0.67 to 0.78 302 .74
Treated with IFL 0.70 0.65 to 0.76 304 0.95 0.72 to 1.26
NOTE. Cases with immunohistochemimstry and genotyping agreement (n  702).
Abbreviations: OS, overall survival; HR, hazard ratio; MMR-D, mismatch repair deficient; MSI-H, microsatellite instability high; MMR-I, mismatch repair intact;
MSI-L/S, microsatellite instability low/stable; FU, fluorouracil; LV, leucovorin; IFL, irinotecan plus FU and LV.
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Fig 2. (A) Overall survival for mismatch
repair (MMR) status by treatment groups
(n  702); (B) disease-free survival for
MMR status by treatment groups (n 
702). FU, fluorouracil; LV, leucovorin; MSI
LS, microsatellite instability low/stable;
MSI H, microsatellite instability high; IFL,
irinotecan, fluorouracil, and leucovorin; NA,
not applicable.
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presence of each of the following prognostic factors: sex (treatment
arm P  .088), age (treatment arm P  .064), extracellular mucin
(treatment arm P  .069), tumor location (treatment arm P  .077),
tumor differentiation (treatment arm P  .087), and nodal ratio
(treatment arm P  .039).
DISCUSSION
This large prospective study indicates that FU/LV alone may not be the
optimal regimen for adjuvant treatment of stage III colon cancers that
demonstrate MMR-D. However, although this study provides insight
regarding the clinical behavior of MMR-D/MSI-H colon cancer, nei-
ther FU/LV alone nor IFL is the standard treatment regimen in this
setting. Current data indicate that 6 months of postoperative FU, LV,
and oxaliplatin (FOLFOX) achieves the best result after surgery for
stage III colon cancer.21 Therefore, these results cannot currently be
used to refine patient care.
Substantial data, largely from retrospective trials, indicate that
patients with MMR-D/MSI-H colon cancers achieve improved sur-
vival when compared with those with MMR-I/MSI-L/S tumors.13,14
In retrospective reports, the effect is modest, with a 10% increase in
DFS and no increase in OS for the MMR-D/MSI-H cases. A possible
explanation involves the inclusion of FU in both treatment arms.
Some studies suggest that FU adversely affects outcome for MSI-H
tumors, and the preponderance of data indicate that FU is at best
ineffective in this form of the disease.15-17 It is therefore possible that
equalization of outcome for the MSI-H and non-MSI-H tumors oc-
curred in our study because FU had a negative impact on the MSI-H
tumors that was overcome by adding irinotecan. Because we see a
trend (P  .07) but not a statistically significant association for the
MMR-D/MSI-H subset, it is also possible that FU treatment negates
an improved outcome in these patients, with no differential effect
of irinotecan.
Several lines of evidence indicate that MSI-H tumors should
respond to treatment with irinotecan. In both cultured cells22,23 and
xenografted human CRCs,24 tumors with MSI-H were more sensitive
to irinotecan than those with intact MMR. Small retrospective studies
of rectal cancer25 and metastatic CRC26 found that MSI-H tumor
status predicted favorable outcome after irinotecan therapy. The
mechanism underlying increased sensitivity of MSI-H tumors to iri-
notecan is not well understood. Irinotecan inhibits the catalytic func-
tion of topoisomerase-I by stabilizing covalent complexes formed
between DNA and this enzyme.27 This interaction impedes the
DNA-relegation process, producing single-strand breaks that are
converted into double-strand breaks after replication fork colli-
sion.28 Because double-strand DNA breaks are lethal if not re-
paired before mitosis, any process that inhibits the efficiency of
DNA repair, including loss of MMR proteins, may potentiate tumor
cell death. MSI-H tumors also demonstrate multiple defects in genes
containing microsatellite repeats. These genes include those governing
signal transduction (eg, transforming growth factor  RII29), apopto-
sis (eg, BAX,5 caspase 530), DNA repair (eg, hMSH6, MBD431), pro-
tein modification (eg, SEC63, OGT32), or transcriptional activation
(eg, TCF433). It is possible that it is not the MMR defect itself, but
rather loss of one or more of these genes, which causes increased
irinotecan chemosensitivity.
The primary analysis from CALGB 89803 showed that addition
of irinotecan to weekly bolus FU/LV did not improve DFS or OS in
stage III disease, but did increase lethal and nonlethal toxicity. In the
PETACC-3 trial, 2,333 patients with stage III colon cancer were ran-
domly assigned to adjuvant treatment with biweekly infusional FU,
either alone or with biweekly irinotecan.34 There was no significant
difference in 3-year DFS, the prespecified primary end point (59.9%
for FU/LV, 62.9% for FU plus irinotecan, P  .1). Although this
infusional FU plus irinotecan combination did not show the unac-
ceptable toxicity levels seen with the bolus IFL regimen of CALGB
Table 5. Effect of Tumor MSI Status on Treatment Outcome for DFS
Population 5-Year DFS 95% CI No. Log-Rank P HR 95% CI
All patients analyzed 0.61 0.57 to 0.64 702
Prognostic analysis
All patients with MMR-D/MSI-H tumors 0.67 0.57 to 0.76 96 .15
All patients with MMR-I/MSI-L/S tumors 0.60 0.56 to 0.64 606 0.77 0.53 to 1.12
Predictive analysis within treatment arm
FU/LV
Patients with MMR-D/MSI-H tumors 0.57 0.42 to 0.71 46 .80
Patients with MMR-I/MSI-L/S tumors 0.61 0.55 to 0.66 302 1.07 0.66 to 1.72
IFL
Patients with MMR-D/MSI-H tumors 0.76 0.64 to 0.88 50 .03
Patients with MMR-I/MSI-L/S tumors 0.59 0.53 to 0.64 304 0.53 0.29 to 0.96
Predictive analysis within tumor subtype
MMR-D/MSI-H tumors
FU/LV 0.57 0.42 to 0.71 46 .07
IFL 0.76 0.64 to 0.88 50 0.52 0.25 to 1.07
MMR-I/MSI-L/S tumors
FU/LV 0.61 0.55 to 0.66 302 .93
IFL 0.59 0.53 to 0.64 304 1.01 0.79 to 1.29
NOTE. Cases with immunohistochemistry and genotyping agreement (n  702).
Abbreviations: DFS, disease-free survival; HR, hazard ratio; MMR-D, mismatch repair deficient; MSI-H, microsatellite instability high; MMR-I, mismatch repair intact;
MSI-L/S, microsatellite instability low/stable; FU, fluorouracil; LV, leucovorin; IFL, irinotecan plus FU and LV.
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89803, it failed to demonstrate a significant DFS or OS advantage for
the combination.
This analysis, of a prospective secondary end point of CALGB
89803, shows that DFS may depend on the MMR status of the primary
tumor. Among the subset of patients receiving IFL, those with MMR-
D/MSI-H tumors had significantly longer DFS. A significant differ-
ence observed for the DFS end point but not the OS end point may be
due to the smaller sample size for OS and the potential influence of
subsequent therapy on OS. The DFS end point may also better reflect
the most immediate impact of the protocol treatment. A strength of
this study is that patients were treated on a controlled clinical trial and
observed prospectively; a drawback is that the low prevalence of
MMR-D/MSI-H tumors did not allow sufficient power to detect more
than a trend in the treatment by MMR status interaction with the
available sample size.
We conclude that MMR-D/MSI-H colon cancer may be a clini-
cally distinct subset of stage III disease, with differential response to
adjuvant chemotherapy. Differences in the treatment regimens tested
and standard practice mean that this observation could not immedi-
ately be translated into clinical practice. It is therefore essential that we
conduct new research to determine whether MMR determination can
be used to select optimal chemotherapy. One study to consider is a
randomized trial of patients with stage III MMR-D/MSI-H tumors,
one arm of which eliminates FU/LV from the adjuvant regimen.
Another issue is whether MMR status predicts a differential response
to FOLFOX. In light of recent reports of increased chronic neurotox-
icity with FOLFOX,35 an adjuvant trial of FOLFOX versus irinotecan
and oxaliplatin for patients with stage III MMR-D/MSI-H tumors
may also be indicated.
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